Trends in Mortality in the
Download
1 / 3

Background HAART has improved AIDS-associated morbidity and mortality - PowerPoint PPT Presentation


  • 476 Views
  • Uploaded on

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Background HAART has improved AIDS-associated morbidity and mortality ' - liam


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Slide1 l.jpg

Trends in Mortality in the Pre- & Post-HAART Eras among HIV-Infected Children in the U.S. Perinatal AIDS Collaborative Transmission Study (PACTS) (1986-2004)B. Kapogiannis*1, M. Soe2, S. Nesheim2, EJ. Abrams3, J. Farley4, P. Palumbo5, LJ. Koenig2, and M. Bulterys2National Institute of Child Health and Human Development (NICHD) / National Institutes of Health (NIH) 1, Bethesda, MD; Centers for Disease Control & Prevention (CDC)2, Atlanta, GA; Harlem Hospital, Columbia University3, NYC, NY; University of Maryland4, Baltimore, MD and Dartmouth College5, Hanover, NH.

  • Background

    • HAART has improved AIDS-associated morbidity and mortality

    • Given the bimodal mortality distribution in HIV-infected children, it is important to evaluate temporal effects of HAART among a pure birth cohort with long-term, prospective follow-up.

  • Methods

    • CDC-sponsored multi-center, prospective birth cohort study of HIV-exposed infants enrolled 1986-1999 to monitor MTCT and pediatric HIV progression.

    • HIV-infected children followed through 4/04

    • Average annual mortality calculated for no/mono-therapy (≤12/31/90), mono/dual-therapy (1/1/91-12/31/96) and HAART eras (≥1/1/97)

    • Mortality trends evaluated using survival analysis and Poisson regression

    • Extended Cox proportional-hazards regression models (Cox PH) estimated the effect of HAART on mortality


Slide2 l.jpg

Trends in Mortality in the Pre- & Post-HAART Eras among HIV-Infected Children in the U.S. Perinatal AIDS Collaborative Transmission Study (PACTS) (1986-2004)B. Kapogiannis*1, M. Soe2, S. Nesheim2, EJ. Abrams3, J. Farley4, P. Palumbo5, LJ. Koenig2, and M. Bulterys2National Institute of Child Health and Human Development (NICHD) / National Institutes of Health (NIH) 1, Bethesda, MD; Centers for Disease Control & Prevention (CDC)2, Atlanta, GA; Harlem Hospital, Columbia University3, NYC, NY; University of Maryland4, Baltimore, MD and Dartmouth College5, Hanover, NH.

  • Results

    • Among 364 children, 98 died 61 were < 2 y/o; 18 more were between 2 – 3 y/o.

    • Ten-year survival of those who ever received HAART and of non-HAART recipients was 94% and 45% (P<0.05)

Survival probability among HAART recipients

(defined by age of initiation of HAART) vs. non-recipients


Slide3 l.jpg

Trends in Mortality in the Pre- & Post-HAART Eras among HIV-Infected Children in the U.S. Perinatal AIDS Collaborative Transmission Study (PACTS) (1986-2004)B. Kapogiannis*1, M. Soe2, S. Nesheim2, EJ. Abrams3, J. Farley4, P. Palumbo5, LJ. Koenig2, and M. Bulterys2National Institute of Child Health and Human Development (NICHD) / National Institutes of Health (NIH) 1, Bethesda, MD; Centers for Disease Control & Prevention (CDC)2, Atlanta, GA; Harlem Hospital, Columbia University3, NYC, NY; University of Maryland4, Baltimore, MD and Dartmouth College5, Hanover, NH.

  • Results (cont’d)

    • HAART-associated declines in mortality remained significant after controlling for birth year, CD4%, anthropometrics (HAZ & WAZ) and maternal CDC classification (Cox PH model, HR=0.25: 95%CI 0.08-0.76)

  • Conclusions

    • A significant decrease in annual mortality and a prolongation in survival were seen among HAART recipients in this U.S. perinatal cohort of HIV-infected children

  • Advances in antiretroviral therapy led to commensurate improvements in crude annual mortality rates (Log-Rank test P<0.05)

  • Using Poisson regression to adjust for gender, race, prematurity, era-entry age, AZT prophylaxis, maternal AIDS class and IVDU hx, the mortality rate ratios in the no/mono- and mono/dual- therapy eras were ~30-fold (P<0.01) and ~9-fold(P<0.01) higher, respectively, than in the HAART era


ad